Although the results from phase II studies showed a PFS as well as an OS benefit, negative outcomes were observed in the CORE trial for GBM patients with unmethylated MGMT promoters and in the CENTRIC trial involving 3471 patients with nGBM, indicating that the doses of cilengitide used in these studies were ineffective when combined with TMZ/RT-TMZ for GBM patients (16–18). The gene discussed is MGMT; the disease is glioblastoma.